tlooto
Sign up
Medicine

Second-line treatment after first-line osimertinib without a targetable resistance mechanism: what remains standard?

J. Ancel, S. Baldacci

2026.4.1Respiratory Medicine and Research

DOI: 10.1016/j.resmer.2026.101273

Abstract

Abstract is not available.

Citation format

ANCEL, J.; BALDACCI, S. Second-line treatment after first-line osimertinib without a targetable resistance mechanism: What remains standard? Respiratory Medicine and Research, 2026, 89: 101273.